Skip to main content
Josephine Li, MD, Endocrinology, Boston, MA

Josephine Huang Li MD

Diabetes


Assistant Professor, Harvard Medical School

Join to View Full Profile
  • MGH Diabetes Center50 Staniford St #340Boston, MA 02114

  • Phone+1 617-726-8722

  • Fax+1 617-724-8534

Dr. Li is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Li is an endocrinologist in the Diabetes Unit at Massachusetts General Hospital and faculty at Harvard Medical School. She received her medical degree from Duke University School of Medicine. She completed a residency in internal medicine at Beth Israel Deaconess Medical Center in Boston and her endocrinology fellowship at Massachusetts General Hospital.

    Dr. Li specializes in treating endocrine disorders with a focus on diabetes. She conducts research on the genetic predictors of response to glucose-lowering medications for type 2 diabetes.

Education & Training

  • Mass General Brigham/Massachusetts General Hospital
    Mass General Brigham/Massachusetts General HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 2017 - 2020
  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2014 - 2017
  • Duke University School of Medicine
    Duke University School of MedicineClass of 2014, MD

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2014 - 2026
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Endocrinology, Diabetes and Metabolism
    American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Genetic Variants May Affect Treatment Response to Commonly Prescribed Type 2 Diabetes Medication
    Genetic Variants May Affect Treatment Response to Commonly Prescribed Type 2 Diabetes MedicationJune 3rd, 2023
  • Genetic Variation Linked to Treatment Response to Commonly Prescribed Type 2 Diabetes Medication
    Genetic Variation Linked to Treatment Response to Commonly Prescribed Type 2 Diabetes MedicationJune 5th, 2023

Grant Support

  • Elucidating the pharmacogenetics of the response to GLP-1 receptor agonists for type 2 diabetesMASSACHUSETTS GENERAL HOSPITAL2022–2027

Professional Memberships

Other Languages

  • Chinese (Mandarin)

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: